Clinical Trial Update: Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus [Phase 1]

View source ↗

Summary

Phase 1 trial to determine the maximum safe range of light doses for photodynamic therapy using HPPH in Barrett's esophagus with high-grade dysplasia, carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Barrett Esophagus
• Carcinoma in Situ
• Esophageal Adenocarcinoma
• High-grade Dysplasia

Drugs mentioned

• HPPH (photosensitizer) (HPPH)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Barrett's Esophagus, CIS | Phase 1 | Status: COMPLETED